# Tesamorelin vs Sermorelin: Structure and Pharmacology

> Tesamorelin vs sermorelin: tesamorelin is a stabilized full-length GHRH(1-44) analogue; sermorelin is the truncated GHRH(1-29). How structure, DPP-IV resistance, and the evidence base differ.

Both are GHRH analogues that prompt the body's own growth hormone — but they differ in length, in stability, and in how deep the evidence runs.

## The short version

Tesamorelin vs sermorelin comes down to length and stability. GHRH (the brain's own "make growth hormone" signal) is 44 amino acids long. Tesamorelin keeps the whole 44-residue chain and adds a small fatty-acid tag that stops the body from breaking it down quickly. Sermorelin is a shorter, 29-residue piece of the same signal. Both tell the pituitary to release the body's own growth hormone, but tesamorelin is the more stabilized, better-studied molecule, with two large human trials behind it. Neither is described here as something to inject; this is a structural and pharmacological comparison only.

## Structure: Full-Length GHRH(1-44) vs Truncated GHRH(1-29)

The clearest difference between tesamorelin and sermorelin is chain length. Native human GHRH is a 44-amino-acid peptide. **Tesamorelin** is a synthetic analogue of the full-length GHRH(1-44), with a trans-3-hexenoic acid group bonded to its N-terminus [1]. **Sermorelin** is the truncated GHRH(1-29) — the first 29 amino acids, which carry the receptor-activating core of the molecule.

Both fragments are biologically active because the business end of GHRH sits in that N-terminal region; both bind the same GHRH receptor on pituitary somatotrophs to trigger the body's own growth-hormone release [2]. The full-length-versus-truncated distinction, plus tesamorelin's stabilizing N-terminal tag, is what separates them pharmacologically.

## Stability: The DPP-IV-Resistance Difference

The functional difference follows from chemistry. Native GHRH is rapidly inactivated by DPP-IV, a protease that cleaves the peptide near its N-terminus within minutes. Tesamorelin's trans-3-hexenoic acid modification blocks that DPP-IV cleavage, extending its biological activity relative to native GHRH [1]. That stabilizing tag is the defining feature of the tesamorelin molecule and the reason it was developed.

A narrative review describes tesamorelin as a synthetic human growth-hormone-releasing-factor analogue developed because growth-hormone-releasing-factor analogues may be better tolerated than recombinant human growth hormone, summarizing Phase 3 evidence that it reduced visceral fat in HIV-related lipodystrophy with a good safety profile, while other potential indications appeared less promising [9]. The design intent was a stabilized, better-tolerated way to raise the body's own growth hormone — not a replacement for it.

## Evidence Base and Regulatory Status

The two compounds differ most in how much human evidence stands behind each. **Tesamorelin** is FDA-approved (NDA 022505, 2010) for one indication — reducing excess abdominal fat in HIV-associated lipodystrophy — supported by two pivotal Phase 3 RCTs [3][4], a JAMA hepatic-fat trial [5], and a 2026 meta-analysis of five trials [13]. Every use outside HIV-associated lipodystrophy is off-label.

Both tesamorelin and sermorelin act through the same GHRH-receptor mechanism, and both are growth-hormone secretagogues rather than exogenous growth hormone [2][9]. Where they part company is the depth of the tesamorelin visceral-fat trial record and tesamorelin's stabilizing N-terminal modification. Both are prohibited in sport under the WADA Prohibited List as growth-hormone-axis agents. This page compares structure and pharmacology only; the [full reference list](/references) carries the tesamorelin citations summarized here.

---

A lab-notebook digest of the tesamorelin record — the GHRH(1-44) chemistry sketched, the visceral-fat and IGF-1 trials and the lone cognition study jotted to their sources, and the FDA-only-for-HIV-lipodystrophy scope inked in the margin in red pen; no clinic behind the bench, nothing here compounded or for sale.